Stanford-StartX Fund has supported a $4m round for Imprimed, which is working on precision cancer treatments for dogs.
Imprimed, a US-based precision cancer treatment company, has secured $4m in funding from investors including the Stanford-StartX Fund, the investment vehicle for Stanford University-affiliated accelerator StartX.
Draper Associates led the round, while Murex Partners, Plug & Play Ventures also took part. The total figure includes a previously unannounced $330,000 pre-seed investment led by Plug & Play Ventures.
Imprimed exploits precision medicine technology to help veterinary oncologists identify appropriate chemotherapies for an individual dog. The company is initially focusing…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).